Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SMN-C3 (MV8T2MCK57) 是口服有效的 SMN2 剪接调节剂。SMN-C3可用于脊椎肌肉萎缩 (SMA) 的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,790 | 现货 | ||
5 mg | ¥ 4,420 | 现货 | ||
10 mg | ¥ 6,280 | 现货 | ||
25 mg | ¥ 9,520 | 现货 | ||
50 mg | ¥ 12,800 | 现货 | ||
100 mg | ¥ 17,300 | 现货 | ||
500 mg | ¥ 34,700 | 现货 |
产品描述 | SMN-C3 (MV8T2MCK57) is an orally active modulator of SMN2 splicing, and has the potential to treat spinal muscular atrophy (SMA). |
体内活性 | At P16, the vehicle-treated D7 mice were much smaller than the control group of heterozygous litter pups and were dying. In contrast, D7 mice treated with high doses of SMN-C3 showed a phenotype similar to the heterozygous control.In the D7 mice, SMN-C3 treatment induces a dose-dependent bodyweight gain , with some animals showing a body weight that is ~80% that of heterozygous controls. SMN-C3 normalizes the motor behavior of D7 mice, illustrated by the ability of the mice to right themselves as quickly as heterozygous controls and by their level of locomotor activity. Most importantly, whereas vehicle-treated mice die within 3 weeks after birth with a median survival of 18 days, SMN-C3 treatment increases survival in a dose-dependent manner to a median survival time of 28 days in the low-dose (0.3 mg/kg per day) group. In the two higher-dose groups (1 and 3 mg/kg per day), ~90% of animals survive beyond P65 when the study is completed[1]. |
别名 | MV8T2MCK57 |
分子量 | 416.52 |
分子式 | C24H28N6O |
CAS No. | 1449597-34-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 2.0 mg/mL (4.8 mM), ultrasonic and warming and heat to 60°C
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4008 mL | 12.0042 mL | 24.0085 mL | 60.0211 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SMN-C3 1449597-34-5 Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis MV8T2MCK57 Inhibitor inhibitor inhibit